Status:
COMPLETED
Gingival Crevicular Fluid and Salivary Levels of GDF-15, Smad2, Smad5, Smad6, and IL-6 in Patients With Periodontitis
Lead Sponsor:
Melis Yilmaz
Collaborating Sponsors:
Medipol University
Conditions:
Periodontitis
Periodontal Disease
Eligibility:
All Genders
18+ years
Brief Summary
The dysregulation of the transforming growth factor-beta signaling pathway can lead to inflammation and tissue destruction in the pathogenesis of periodontitis. This study aims to evaluate the levels ...
Eligibility Criteria
Inclusion
- being over 18 years of age;
- having at least 20 natural teeth excluding third molars;
- being systemically healthy
Exclusion
- under 18 years of age;
- had used antibiotics
- had used nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, beta-blockers, calcium channel blockers, anticoagulants, or hormonal contraceptives within the past 6 months;
- had systemic diseases such as diabetes mellitus, rheumatoid arthritis, cardiovascular diseases, epilepsy, renal or hepatic disorders, or viral infections like HIV/AIDS;
- pregnant or breastfeeding;
- current smokers or had a history of alcoholism;
- had received nonsurgical periodontal therapy within the last 6 months or surgical periodontal treatment within the last 12 months;
- had fewer than 20 natural teeth (excluding third molars);
- had fixed orthodontic appliances.
Key Trial Info
Start Date :
April 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 17 2024
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT07201142
Start Date
April 3 2023
End Date
December 17 2024
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medipol University
Istanbul, Istanbul, Turkey (Türkiye), 34810